John Rice Joins Panel Addressing Biotechnology Startups
What are some of the challenges of commercializing biotechnology research? How did the success of pioneering biotech companies like Genentech help change the way we think about the market for biotech, now a multibillion-dollar industry? What venture investors look for before supporting a promising pharmaceutical discovery?
Those were among the questions recently addressed during a panel sponsored by the Cleveland-based Harrington Discovery Institute. Cincytech Life Sciences Managing Director John Rice, Ph.D., was among the participants discussing how to attract the pharmaceutical industry to invest in drug discovery and development. He was joined by Harrington Discovery Institute Investment Advisors Graeme Martin, PhD, Chief Investment Officer, ALSA Ventures; and Jesse Treu, PhD, Partner Emeritus, Domain Associates. The session was moderated by Consultant Rebecca Braun.
Rice is chairman of Harrington Discovery Institute Investment Advisory Board.
Founded in 2012, Harrington Discovery Institute’s mission is to accelerate promising discoveries into medicines for unmet needs. Harrington Discovery Institute at University Hospitals in Cleveland, Ohio supports physician-scientists who strive to change the standard of care in medicine. Our model has expanded to include all scientists with discoveries in unmet medical needs, with a particular focus on brain health, rare diseases, COVID-19 and major diseases affecting society.